retatrutide triple agonist glp-1 gip glucagon phase 2 obesity trial just had its biggest data year yet. In 2026, Eli Lilly's GLP-1/GIP/glucagon receptor posted two major 3 readouts: TRIUMPH-1 (obesity, 2,339 participants) showed a 28.3% average body weight Retatrutide (40mg) - theragenetics

Updated February 2026

Different types of insurance handle GLP-1 medications differently

In conclusion, we suggested that GLP- 1R is expressed not only in insulinomas but also in subclinical insulinomas in PanNETs

11 The SELECT trial showed a 20% reduction in the risk of these events in adults with obesity and cardiovascular disease but no prior history of diabetes

While no amount of money can reverse a chronic medical condition, compensation can provide essential financial stability

PLoS ONE 11(12):e0168396 Disclosures PB has acted as a consultant for Bayer, Bristol-Myers Squibb, Boehringer Ingelheim, Sanofi, Novo Nordisk and Horizon Pharma